MBX Biosciences Execs to Present at Key Investor Conferences

Event summary

MBX Biosciences CEO Steve Hoerter and CMO Sam Azoulay to present at Morgan Stanley and Stifel investor conferences in September 2026.
Fireside chats and 1x1 meetings scheduled for September 16 and September 30, 2026.
Webcasts available live and archived for 90 days on MBX Biosciences' investor relations website.
Company advancing pipeline including canvuparatide (Phase 3) for chronic hypoparathyroidism and obesity portfolio candidates.

The big picture

MBX Biosciences' participation in high-profile investor conferences underscores its push to engage with the investment community amid a critical phase of clinical development. The company's focus on precision peptide therapies aligns with broader industry trends toward targeted treatments for metabolic disorders, but success will hinge on demonstrating differentiated efficacy and safety profiles in crowded therapeutic areas.

What we're watching

Pipeline Progress: How Phase 3 data for canvuparatide will impact investor sentiment and potential partnerships.
Market Positioning: Whether MBX Biosciences can differentiate itself in the competitive obesity therapeutics space.
Execution Risk: The pace at which preclinical candidates MBX 5765 and MBX 6180 advance toward clinical trials.